Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00331851
Status:
COMPLETED
Last Update Posted:
2017-01-26
First Post:
2006-05-30
Brief Title:
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Liraglutide Effect and Action in Diabetes LEAD-5 Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 DiabetesA Six-month Randomised Double-blind Parallel-group Multi-centre Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LEAD-5
Brief Summary:
This trial is conducted in Africa Asia Europe and South America This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None